



## **AdBio partners welcomes Inserm Transfert as investor in second fund – AFB Fund II**

**The two entities strengthen partnership to support, grow and finance Europe’s most innovative life science startups**

**Paris, France, May 3, 2022** – AdBio partners, an AMF-regulated (the French financial market authority) investment company dedicated to life sciences, and Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research (Inserm) with a focus on technology transfer in life sciences and creating value from Inserm’s innovations, today announce that Inserm Transfert has joined the investors in AdBio partners’ second fund - AFB Fund II.

“We’re delighted to welcome Inserm Transfert as investor in our second fund. It is a prestigious partner within the French and European life sciences industry. We share a single vision: promoting entrepreneurship in French academic research into health and helping to develop an ecosystem, which sometimes has a silo mentality but is also rich in innovation and talented individuals. This is the goal that we will pursue together,” said Alain Huriez, chairman and managing partner at AdBio partners.

This partnership will make it easier for the most innovative life sciences startups to get off the ground and find funding, whilst also strengthening entrepreneurial skills among scientists with a background in academic research, such as those at Inserm. AdBio partners’ portfolio already contains a number of companies whose IP originates from Inserm, such as Alderaan Biotechnology, DiogenX, Tridek-One and Thabor Therapeutics. This is a clear demonstration of the work already undertaken by the two partners in recent years.

“We’re very familiar with the AdBio partners team, their network and their experience as investor-entrepreneurs in early-stage healthcare companies. This combination of factors convinced us that it is the ideal partner for strengthening the role of entrepreneurship in our value-adding strategy, as we look for practical ways to bring innovative technologies to the market for the benefit of all,” added Pascale Augé, chairman of the Executive Management Board at Inserm Transfert.

Inserm Transfert joins the international limited partners who have invested in AdBio partners’ second fund. The [initial closing announced in September 2021](#) reached €86 million (\$102M). Among these other investors are the European Investment Fund (EIF), the French Seed Fund 2 (FNA 2), managed by Bpifrance on behalf of the French State as part of the future investments program, Boehringer Ingelheim Venture Fund, Pierre Fabre, various family offices and the management of AdBio partners.

“It’s crucial that we continue to develop early-stage financing for new companies in France and Europe. AdBio partners has put together a team of experts to meet this challenge and to create startups in direct partnership with the scientists and academic researchers at the root of the innovations; Inserm is a major French player in this sector,” explained Matthieu Coutet, managing partner at AdBio partners.

Inserm Transfert has helped startups from Inserm raise over €1.66 billion (\$1.78bn) since 2010. Around a dozen startups are created every year based on innovations researched by Inserm.



### **About Inserm Transfert**

Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research (Inserm), is responsible for the value creation of innovations at Inserm and its academic partners in human health, and promotes long-term technology transfers in line with international best practices. Inserm Transfert SA was founded in 2000. It manages, under a Public Service Management Contract (Délégation de Service Public), the entire promotion and transfer of knowledge emerging from the Inserm research laboratories to the industrial world, from invention disclosure to industrial partnerships and startup incorporation. Inserm Transfert also offers services relating to setting up and managing national, European and international projects, as well as supporting the technology transfer of clinical research and health data/databases. In 2009, Inserm Transfert and Inserm established an investment fund to finance proofs of concept. In 2005, Inserm Transfert Initiative, a dedicated seed money fund for life sciences, was created. Since 2017 a pathway for pre-entrepreneurship supports researchers/inventors who aspire to become involved in entrepreneurship.

[www.inserm-transfert.fr](http://www.inserm-transfert.fr)

### **About AdBio partners**

AdBio partners (previously Advent France Biotechnology) is an AMF-regulated (the French financial market authority) company that invests in a range of sectors within life sciences - specifically in therapeutics-oriented projects.

AdBio partners' unique strategy combines early-stage investments in promising enterprises and strong entrepreneurial support to strengthen the company's growth.

Created in 2016, AdBio partners has made 17 European investments in France, Belgium, Spain and Ireland.

AdBio partners has developed strong relationships within the European innovation ecosystem; as a result, it has attracted international VC syndicates to its portfolio companies.

The operational team is managed by Alain Huriez and Matthieu Coutet. It has appointed a number of investment professionals with long-standing track records in entrepreneurial ventures, combined with strong scientific and medical expertise.

[www.adbio.partners](http://www.adbio.partners)

---

### **Press and analyst contacts**

#### **AdBio partners**

Andrew Lloyd & Associates

[Celine Gonzalez](#) / [Juliette Schmitt](#)

Tel.: +44 1273 952 481

[@ALA\\_Group](#)

#### **Inserm Transfert**

Acorelis

[Gilles Petitot](#)

Tel.: +33 (0)6 20 27 65 94

[Ingrid Hargot](#)

Tel: +33 1 55 03 01 44

---